Division of Danaher Corp.
Latest From Hybritech Inc.
For an industry that's dependent on innovation, less money is being invested in US biotechnology research and development by venture capital and government sources, and the Pharmaceutical Research & Manufacturers of America (PhRMA) revealed at its annual meeting in San Diego that R&D investment by its 31 members also has slipped to $48.5 billion in 2012 from $48.6 billion a year earlier and a high over the past decade of $50.7 billion in 2010.
Adamis Pharmaceuticals has appointed two new non-employee directors to its board: Kenneth Cohen, chairman of the biopharmaceutical company Pier Pharmaceuticals, and Karen Klause, managing director of EMEA for the biotech company Response Biomedical. Mr Cohen was co-founder, president and CEO of Somaxon Pharmaceuticals; he has also held roles at Synbiotics and Canji (Schering-Plough, now Merck). Ms Klause has held previous roles at Hybritech (Lilly), Digirad Corporation and CMP Media.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Danaher Corp.
- Senior Management
G. R Bell, Pres. & CEO
Craig A Halverson, Tech. Acquisition Analyst
Joseph Carangelo, Mgr., Bus. Dev.
Dr. James R Ludwig, Research Mgr.
- Contact Info
Phone: (619) 455-6700
P.O. Box 269006
San Diego, CA 92196-9006
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.